Breaking News

These drugs once tore apart the FDA. Today, they might be some patients’ best hope  

April 8, 2026
Pharmalot Columnist, Senior Writer
Hawken Miller at his home in Newport Beach, Calif.
Sandy Huffaker for STAT

STAT+ | A decade ago, these drugs tore apart the FDA. Today, they might be some patients’ best hope

An exon-skipping drug delivered striking results, but the Duchenne muscular dystrophy field has been burned before and some fear history could repeat.

By Jason Mast


STAT+ | Steve Ubl to step down as CEO of PhRMA

The powerful pharmaceutical industry lobbying group PhRMA has faced off with both Republicans and Democrats over efforts to rein in drug prices.

By John Wilkerson


STAT+ | 23andMe finds genetic changes appear to help predict response to GLP-1 drugs for weight loss

New research by the 23andMe Research Institute suggests genetic changes appear to help predict whether patients will lose substantial weight on GLP-1 drugs.

By Matthew Herper



Adobe

STAT+ | Everyone agrees AI scribes are increasing health care costs. No one agrees what to do about it

It's unclear how the health care industry will handle technology-driven inflation, especially in the face of political pressure to lower health care costs.

By Brittany Trang


Opinion: What American hospitals can learn from India about waste

When these medical students visited hospitals in India, they learned that medicine does not have to be so bad for the environment.

By Srinidhi Polkampally and Bhav Jain


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Pharmalot? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2026, All Rights Reserved.

No comments